BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deray G, Rouviere O, Bacigalupo L, Maes B, Hannedouche T, Vrtovsnik F, Rigothier C, Billiouw JM, Campioni P, Ferreiros J, Devos D, Alison D, Glowacki F, Boffa JJ, Marti-Bonmati L. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol. 2013;23:1250-1259. [PMID: 23212275 DOI: 10.1007/s00330-012-2705-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Zhang B, Liang L, Chen W, Liang C, Zhang S. An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis. PLoS One 2015;10:e0129720. [PMID: 26076348 DOI: 10.1371/journal.pone.0129720] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
2 Puech P, Sufana-Iancu A, Renard B, Lemaitre L. Prostate MRI: can we do without DCE sequences in 2013? Diagn Interv Imaging 2013;94:1299-311. [PMID: 24211261 DOI: 10.1016/j.diii.2013.09.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
3 Demine S, Balhuizen A, Debaille V, Joosten L, Fereau M, Chilla SNM, Millard I, Scharfmann R, Egrise D, Goldman S, Marchetti P, Gotthardt M, Laurent S, Burtea C, Eizirik DL. Imaging of Human Insulin Secreting Cells with Gd-DOTA-P88, a Paramagnetic Contrast Agent Targeting the Beta Cell Biomarker FXYD2γa. Molecules 2018;23:E2100. [PMID: 30134599 DOI: 10.3390/molecules23092100] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
4 Young LK, Matthew SZ, Houston JG. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals. Eur Radiol 2019;29:1922-30. [PMID: 30276674 DOI: 10.1007/s00330-018-5737-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
5 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol C, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018;69:136-50. [PMID: 29706252 DOI: 10.1016/j.carj.2017.11.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
6 Ludwig DR, Shetty AS, Broncano J, Bhalla S, Raptis CA. Magnetic Resonance Angiography of the Thoracic Vasculature: Technique and Applications. J Magn Reson Imaging 2020;52:325-47. [PMID: 32061029 DOI: 10.1002/jmri.27067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Steinkohl F, Pichler R, Junker D. Short review of biparametric prostate MRI. Memo 2018;11:309-12. [PMID: 30595756 DOI: 10.1007/s12254-018-0458-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
8 Soyer P, Dohan A, Patkar D, Gottschalk A. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. J Magn Reson Imaging. 2017;45:988-997. [PMID: 27726239 DOI: 10.1002/jmri.25486] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
9 Gorelik Y, Yaseen H, Heyman SN, Khamaisi M. Negligible Risk of Acute Renal Failure Among Hospitalized Patients After Contrast-Enhanced Imaging With Iodinated Versus Gadolinium-Based Agents. Invest Radiol 2019;54:312-8. [PMID: 30480553 DOI: 10.1097/RLI.0000000000000534] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 12.3] [Reference Citation Analysis]
11 Shaffer KM, Parikh MR, Runge TM, Perez SD, Sakaria SS, Subramanian RM. Renal safety of intravenous gadolinium-enhanced magnetic resonance imaging in patients awaiting liver transplantation: RENAL SAFETY OF MRI IN LIVER TRANSPLANT CANDIDATES. Liver Transpl 2015;21:1340-6. [DOI: 10.1002/lt.24118] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Azzouz M, Rømsing J, Thomsen HS. Fluctuations in eGFR in relation to unenhanced and enhanced MRI and CT outpatients. Eur J Radiol 2014;83:886-92. [PMID: 24656402 DOI: 10.1016/j.ejrad.2014.02.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
13 Gorelik Y, Bloch-Isenberg N, Yaseen H, Heyman SN, Khamaisi M. Acute Kidney Injury After Radiocontrast-Enhanced Computerized Tomography in Hospitalized Patients With Advanced Renal Failure: A Propensity-Score-Matching Analysis. Invest Radiol 2020;55:677-87. [PMID: 32101881 DOI: 10.1097/RLI.0000000000000659] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
14 Gheuens E, Daelemans R, Mesens S. Dialysability of Gadoteric Acid in Patients With End-Stage Renal Disease Undergoing Hemodialysis: . Investigative Radiology 2014;49:505-8. [DOI: 10.1097/rli.0000000000000045] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
15 van der Molen AJ. Diagnostic Efficacy of Gadolinium-Based Contrast Media. In: Thomsen HS, Webb JAW, editors. Contrast Media. Berlin: Springer Berlin Heidelberg; 2014. pp. 181-91. [DOI: 10.1007/174_2013_896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Lim J, Park EA, Song YS, Lee W. Single-Dose Gadoterate Meglumine for 3T Late Gadolinium Enhancement MRI for the Assessment of Chronic Myocardial Infarction: Intra-Individual Comparison with Conventional Double-Dose 1.5T MRI. Korean J Radiol 2018;19:372-80. [PMID: 29713214 DOI: 10.3348/kjr.2018.19.3.372] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
17 Alfano G, Fontana F, Ferrari A, Solazzo A, Perrone R, Giaroni F, Torricelli P, Cappelli G. Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment. Magn Reson Imaging 2020;70:1-4. [PMID: 32112811 DOI: 10.1016/j.mri.2020.02.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
18 Chatterjee A, He D, Fan X, Wang S, Szasz T, Yousuf A, Pineda F, Antic T, Mathew M, Karczmar GS, Oto A. Performance of Ultrafast DCE-MRI for Diagnosis of Prostate Cancer. Acad Radiol 2018;25:349-58. [PMID: 29167070 DOI: 10.1016/j.acra.2017.10.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
19 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
20 Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ. Gadolinium-based contrast agents: A comprehensive risk assessment. J Magn Reson Imaging 2017;46:338-53. [PMID: 28083913 DOI: 10.1002/jmri.25625] [Cited by in Crossref: 168] [Cited by in F6Publishing: 113] [Article Influence: 42.0] [Reference Citation Analysis]
21 Ponrartana S, Moore MM, Chan SS, Victoria T, Dillman JR, Chavhan GB. Safety issues related to intravenous contrast agent use in magnetic resonance imaging. Pediatr Radiol 2021;51:736-47. [PMID: 33871726 DOI: 10.1007/s00247-020-04896-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Servais L, Boschetti G, Meunier C, Gay C, Cotte E, François Y, Rozieres A, Fontaine J, Cuminal L, Chauvenet M, Charlois AL, Isaac S, Traverse-Glehen A, Roblin X, Flourié B, Valette PJ, Nancey S. Intestinal Conventional Ultrasonography, Contrast-Enhanced Ultrasonography and Magnetic Resonance Enterography in Assessment of Crohn's Disease Activity: A Comparison with Surgical Histopathology Analysis. Dig Dis Sci 2021. [PMID: 34052948 DOI: 10.1007/s10620-021-07074-3] [Reference Citation Analysis]
23 Nadjiri J, Pfeiffer D, Straeter AS, Noël PB, Fingerle A, Eckstein HH, Laugwitz KL, Rummeny EJ, Braren R, Rasper M. Spectral Computed Tomography Angiography With a Gadolinium-based Contrast Agent: First Clinical Imaging Results in Cardiovascular Applications. J Thorac Imaging 2018;33:246-53. [PMID: 29863589 DOI: 10.1097/RTI.0000000000000335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 Junker D, Steinkohl F, Fritz V, Bektic J, Tokas T, Aigner F, Herrmann TRW, Rieger M, Nagele U. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations? World J Urol 2019;37:691-9. [PMID: 30078170 DOI: 10.1007/s00345-018-2428-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 12.3] [Reference Citation Analysis]
25 Dohan A, Taylor S, Hoeffel C, Barret M, Allez M, Dautry R, Zappa M, Savoye-Collet C, Dray X, Boudiaf M, Reinhold C, Soyer P. Diffusion-weighted MRI in Crohn's disease: Current status and recommendations. J Magn Reson Imaging. 2016;44:1381-1396. [PMID: 27249184 DOI: 10.1002/jmri.25325] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 11.2] [Reference Citation Analysis]
26 Prince MR, Weinreb JC. Notice of Withdrawal: MR Imaging and Gadolinium: Reassessing the Risk of Nephrogenic Systemic Fibrosis in Patients with Severe Renal Disease. Radiology 2018;286:120-1. [PMID: 29261455 DOI: 10.1148/radiol.2017172255] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
27 Martino F, Amici G, Rosner M, Ronco C, Novara G. Gadolinium-Based Contrast Media Nephrotoxicity in Kidney Impairment: The Physio-Pathological Conditions for the Perfect Murder. J Clin Med 2021;10:E271. [PMID: 33450989 DOI: 10.3390/jcm10020271] [Reference Citation Analysis]
28 Murphy DJ, Kwong RY. Contrast Agents in Cardiovascular Magnetic Resonance Imaging. In: Kwong RY, Jerosch-herold M, Heydari B, editors. Cardiovascular Magnetic Resonance Imaging. New York: Springer; 2019. pp. 127-43. [DOI: 10.1007/978-1-4939-8841-9_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Tan CH, Hobbs BP, Wei W, Kundra V. Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol 2015;204:W439-48. [PMID: 25794093 DOI: 10.2214/AJR.14.13373] [Cited by in Crossref: 63] [Cited by in F6Publishing: 26] [Article Influence: 10.5] [Reference Citation Analysis]
30 Murphy DJ, Aghayev A, Steigner ML. Vascular CT and MRI: a practical guide to imaging protocols. Insights Imaging 2018;9:215-36. [PMID: 29541955 DOI: 10.1007/s13244-018-0597-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
31 Siauve N, Chalouhi GE, Deloison B, Alison M, Clement O, Ville Y, Salomon LJ. Functional imaging of the human placenta with magnetic resonance. American Journal of Obstetrics and Gynecology 2015;213:S103-14. [DOI: 10.1016/j.ajog.2015.06.045] [Cited by in Crossref: 75] [Cited by in F6Publishing: 55] [Article Influence: 12.5] [Reference Citation Analysis]